Clinical Trial Update: Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating hypofractionated radiotherapy in combination with durvalumab (MEDI4736) and tremelimumab in patients with metastatic melanoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• Tremelimumab (tremelimumab)
• durvalumab (MEDI4736) (durvalumab)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Metastatic, Melanoma | Phase 1 | Status: COMPLETED